Pharmacological Ascorbate for Lung Cancer

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

A Phase II Trial of High-Dose Ascorbate in Stage IV Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02420314
• Other study ID #: 201412760
• Secondary ID: 3P30CA086862
• Status: Completed
• Phase: Phase 2
• Start date: April 2015
• Est. completion date: August 27, 2022

Study information

• Verified date: May 2024
• Source: University of Iowa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of non-small cell lung cancer (NSCLC) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.

Description:

Standard treatment for non-small cell lung cancer (NSCLC) involves a combined therapy of paclitaxel and carboplatin. These drugs are administered once every 21 days. This study adds high dose ascorbic acid (75g per infusion) twice per week for up to 4 cycles of therapy.

Participants will:

• receive high doses of intravenous (IV) ascorbate two times a week during each 3 week chemotherapy.

• have blood samples drawn to measure blood ascorbate levels once every 21 days

• have blood samples drawn to measure iron and ferritin levels before treatment, then on cycles 1 and 3.

The active therapy portion of this study lasts for 4 months. After that is completed, participants will go back to standard therapy for their cancer. Participants will continue to have life-long follow-up for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: August 27, 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• newly diagnosed stage IIIB or IV non -small cell lung cancer. The potential participant must not have received first-line cytotoxic therapy. Prior use of first-line EGFR inhibitors or ALK inhibitors is allowed if there was progression on therapy.

• CNS metastasis is allowed if the metastasis is treated and there are no signs of progression following treatment. The potential participant must be off steroids for at least 3 days and be stable.

• At least 18 years of age

• ECOG performance status of 0, 1, or 2

• absolute neutrophil count (ANC) of at least 1500 cells per mm³

• platelet count of at least 100,000 cells per mm³

• hemoglobin of at least 8 g/dL

• creatinine within 1.5 times the upper limit of normal

• total bilirubin within 1.5 times the upper limit of normal

• ALT within 3 times the institutional upper limit of normal

• AST within 3 times the institutional upper limit of normal

• the participant must tolerate a 15g ascorbate test infusion (screening dose)

• patients who received prior treatment with curative intent must have experienced a treatment-free interval of at least 6 months since the last treatment

• the participant must not be pregnant, be willing to have a pregnancy test done if deemed necessary, and be willing to use adequate birth control during the study

• not breastfeeding

• independently able to provide consent (legally authorized representative and/or power of attorney is not allowed)

Exclusion Criteria:

• known sensitizing EGFR mutations or ALK gene rearrangements if the participant has not yet tried EGFR or ALK inhibitor therapies. If the potential participant's biopsy did not allow for gene analysis (inconclusive, not enough tissue), the patient is considered eligible for the study. Enrollment on this clinical trial after progression on targeted therapy is allowed

• 50% or greater PD-L1 expression (patients with unknown PD-L1 expression or when PD-L1 expression can't be determined due to insufficient tumor sample or other reasons remain eligible)

• receiving warfarin therapy and cannot tolerate drug substitution

• active hemoptysis within 1 week of screening (more than 1/2 teaspoon of blood per day)

• actively receiving insulin at the time of ascorbate infusion

• G6PD deficiency

• leptomeningeal disease

• potential participants cannot be on the following drugs: flecainide, methadone, amphetamines, quinidine, or chlorpropamide.

• known active invasive malignancy other than the lung cancer under therapy (non-melanoma skin cancer or carcinoma in situ of the cervix or bladder are exempted)

• potential participants may not enroll in, or be actively receiving treatment from, a therapeutic clinical trial for their cancer. Observational studies (including imaging studies) are acceptable.

• uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness / social situations that would limit compliance with study requirements

• known HIV positive individuals cannot be enrolled in this trial because high-dose ascorbate is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral agents

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

Intervention

Drug:
• Paclitaxel
Administered intravenously (IV) Prescribed at 200 mg/m2 (standard dose) Given once every 21 days (i.e., one cycle) Up to 4 cycles are administered depending on disease response
• Carboplatin
Administered intravenously (IV) Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose) Given once every 21 days (i.e., one cycle) Up to 4 cycles are administered depending on disease response
• Ascorbic Acid
Administered intravenously (IV) 75g per infusion Two infusions per week 1 cycle is 3 weeks given up to 4 cycles may be given while chemotherapy if delayed due to low counts

Locations

Country	Name	City	State
United States	Holden Comprehensive Cancer Center	Iowa City	Iowa

Sponsors (5)

Lead Sponsor	Collaborator
Joseph J. Cullen, MD, FACS	Holden Comprehensive Cancer Center, McGuff Pharmaceuticals, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Furqan M, Abu-Hejleh T, Stephens LM, Hartwig SM, Mott SL, Pulliam CF, Petronek M, Henrich JB, Fath MA, Houtman JC, Varga SM, Bodeker KL, Bossler AD, Bellizzi AM, Zhang J, Monga V, Mani H, Ivanovic M, Smith BJ, Byrne MM, Zeitler W, Wagner BA, Buettner GR, — View Citation

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Sc — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor Response	From cycle 1, day 1, to documented disease progression in CT imaging as described by RECIST criteria	every 2 months for up to 5 years post treatment
Secondary	Progression Free Survival (PFS)	The time (in months) it takes for disease to progress as defined by RECIST criteria. Timeframe will be from cycle 1, day 1 to date of progression.	every 2 months for up to 5 years post treatment
Secondary	Overall Survival (OS)	Time, measured in months, from cycle 1 day 1 until date of death from any cause	every 2 months for up to 5 years post treatment
Secondary	Adverse Event Frequency	Categorize and quantify using the Common Terminology Criteria for Adverse Events (CTCAE) v. 4 from cycle 1 day 1 through 1 month post-infusion	monthly for up to 6 months